

Title:
Atypical hemolytic uremic syndrome triggered by acute pancreatitis

Authors:
Qing Yang, Qiang Geng, Shubei Chen, Ying Lin, Yong Ye

DOI: 10.17235/reed.2025.11114/2025

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:

Yang Qing, Geng Qiang, Chen Shubei, Lin Ying, Ye Yong. Atypical hemolytic uremic syndrome triggered by acute pancreatitis. Rev Esp Enferm Dig 2025. doi: 10.17235/reed.2025.11114/2025.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

CC 11114

Atypical hemolytic uremic syndrome triggered by acute pancreatitis

Qing Yang¹, Qiang Geng², Shubei Chen¹, Ying Ling³, Yong Ye¹

Departments of ¹Gastroenterology and ³Endoscopic Medicine and ²Second Department of Oncology. The Second People's Hospital of Neijiang. Sichuan Province, China

Correspondence: Qing-Yang

e-mail: 2271869843@qq.com

Authors' contributions: Data curation: Y. Y.; formal analysis: Y. L.; investigation: Q. Y.; resources: S. C.; and writing-original draft: Q. G.

Conflict of interest: The authors declare no conflict of interest.

Artificial intelligence: The authors declare that no artificial intelligence (AI) or AI-assisted technologies were used in the elaboration of the article.

Keywords: Atypical hemolytic uremic syndrome. Thrombotic microangiopathy. Eculizumab. Plasma exchange.

Dear Editor,

The patient was a 72-year-old male with a history of untreated gallstones who presented to the hospital due to abdominal pain lasting for one day. Abdominal computed tomography (CT) scan revealed acute pancreatitis and gallstones (Fig. 1A) and the preliminary diagnosis indicated mild acute gallstone-pancreatitis (1). After 12 hours of routine treatment, the patient developed hemoglobinuria and hematochezia. Further examination revealed acute kidney injury, hemolytic anemia (with elevated total and indirect bilirubin levels), thrombocytopenia, and severe

coagulation dysfunction. Plasma exchange (PE) was started, pushing fresh frozen plasma (3,000 ml/session, once daily). Furthermore, the peripheral blood smears showed fragmented erythrocytes, elevated LDH, decreased C3 levels, and normal C4 levels. Stool culture and Coombs test results were negative, and ADAMTS13 activity was 60.5 %. The final diagnosis was atypical hemolytic uremic syndrome (aHUS) caused by acute pancreatitis. After three PE sessions, his condition gradually improved and coagulation normalized. However, due to financial constraints, he discontinued PE and eculizumab, opting for hemodialysis instead. Eventually, the patient progressed to chronic kidney failure. Figure 1B illustrates the biochemical and hematological changes during treatment and the timing of PE.

Discussion

Thrombotic microangiopathy (TMA) is a group of acute clinical syndromes characterized by hemolytic anemia, consumptive thrombocytopenia, and microvascular thrombosis, and the kidney is the most commonly affected organ. aHUS is a TMA, with triggers for activation of the complement alternative pathway, such as infection and pregnancy, present in 70-80 % of patients. It should be distinguished from typical hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC) (2). The pancreas acts as both a target and effector in inflammation, with complement cascade interactions playing a key role. Complement activation triggers acinar cell damage in early pancreatitis, leading to autodigestion by pancreatic enzymes, which further cleave and activate complement factors (3). Therefore, pancreatitis can cause complement system dysfunction, leading to aHUS. Although rare, similar cases have been reported. In this case, the patient developed hemoglobinuria about 36 hours after abdominal pain onset, aligning with prior findings (4). Specific treatments for aHUS include eculizumab and PE. Eculizumab inhibits the complement pathway, thereby reducing endothelial damage, thrombosis, and kidney injury. PE removes defective mutant complement proteins and autoantibodies, and also avoids volume overload in patients with kidney injury. Before eculizumab became available to treat aHUS, PE was the preferred treatment

(5).

In this case, the patient improved significantly after PE, but insufficient treatment led to serious sequelae. Thus, hemodialysis cannot replace PE in aHUS patients, and early, accurate and adequate treatment is crucial for prognosis.

References

1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2012;62(1):102-11. DOI: 10.1136/gutjnl-2012-302779
2. Fakhouri F, Zuber J, Frémeaux-Bacchi V, et al. Haemolytic uraemic syndrome. *Lancet* 2017;390(10095):681-96. DOI: 10.1016/S0140-6736(17)30062-4
3. Bettac L, Denk S, Seufferlein T, et al. Complement in pancreatic disease-perpetrator or savior? *Front Immunol* 2017;8:15. DOI: 10.3389/fimmu.2017.00015
4. Tsubasa K, Masahumi F, Yuuichirou R, et al. Atypical hemolytic uremic syndrome secondary to pancreatitis: a case report. *Cureus* 2023;15(2):e35434.
5. Fakhouri F, Schwotzer N, Frémeaux-Bacchi V. How I diagnose and treat atypical hemolytic uremic syndrome. *Blood* 2023;141(9):984-95. DOI: 10.1182/blood.2022017860




Fig. 1. A. Computed tomography (CT) scan of the patient's abdomen. Gallbladder stones (yellow arrows) and peripancreatic effusion (red arrows). B. Biochemical and hematological progression over the course of admission and the timing of plasma exchange (PE).